Premium
Magnetic Resonance Imaging‐Guided Drug Delivery to Breast Cancer Stem‐Like Cells
Author(s) -
Sun Yujin,
Kim Hoe Suk,
Kang Sukmo,
Piao Yin Ji,
Jon Sangyong,
Moon Woo Kyung
Publication year - 2018
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201800266
Subject(s) - doxorubicin , drug delivery , cancer research , magnetic resonance imaging , chemistry , breast cancer , chemotherapy , medicine , cancer , materials science , nanotechnology , surgery , radiology
The feasibility of detecting breast cancer stem‐like cells (BCSCs) with magnetic resonance imaging using extradomain‐B of fibronectin (EDB‐FN)‐specific peptide (APT EDB )‐conjugated thermally cross‐linked superparamagnetic iron oxide nanoparticles (APT EDB ‐TCL‐SPIONs) is previously demonstrated. Here, doxorubicin (Dox)‐loaded APT EDB ‐TCL‐SPIONs (Dox@APT EDB ‐TCL‐SPIONs) are generated and their theranostic ability in a BCSC xenograft mouse model is assessed. The Dox@APT EDB ‐TCL‐SPIONs enable more efficient delivery of Dox to tumors than nontargeted Dox@TCL‐SPIONs. Much greater inhibition of BCSC tumor growth is observed after treatment with the Dox@APT EDB ‐TCL‐SPIONs than with either Dox@TCL‐SPIONs or free Dox. Hypointense signals are observed in the majority of the mice in postcontrast but not precontrast T2*‐weighted MR images of tumors 7 days after treatment with Dox@APT EDB ‐TCL‐SPIONs. An inverse correlation is observed between signal intensity and both EDB‐FN expression and response to chemotherapy. The data indicate Dox@APT EDB ‐TCL‐SPIONs can detect BCSCs within tumors by targeting EDB‐FN‐expressing cells. These nanoparticles thus have theranostic potential in breast cancer.